Moreover, TP53 mutation contributes to chemotherapy resistance such as chlorambucil (CLB); however, this is not the only mechanism of drug resistance in CLL, as patients harboring wild-type p53 also represent resistance to treatment [448]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.